Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Epacadostat in First-line NSCLC
NCT03348904Phase 3Terminated
- Sponsor
- Incyte
- Start
- Dec 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of epacadostat in non-small cell lung cancer (NSCLC), sponsored by Incyte. Started Dec 2017; status: terminated.
02
Drugs
epacadostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03348904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03348904.